Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* No current or prior anti-HIV treatment, including ART medications received for prevention (preexposure prophylaxis \[PrEP\]), or postexposure prophylaxis (PEP) within 12 weeks of screening~* Plasma HIV-1 ribonucleic acid (RNA) ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at screening~* Cluster of differentiation 4+ (CD4+) cell count \> 200 cells/mm\^3~Key Exclusion Criteria:~* Anticipated to start HIV-1 therapy during the study period~* Active participation in another study of investigational or approved ART agents~* A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within the 30 days prior to screening~* Participants with positive hepatitis C antibody at screening~* Chronic hepatitis B virus (HBV) infection~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bictegravir 5 mg (Type: EXPERIMENTAL): Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
- Bictegravir 25 mg (Type: EXPERIMENTAL): Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
- Bictegravir 50 mg (Type: EXPERIMENTAL): Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
- Bictegravir 100 mg (Type: EXPERIMENTAL): Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to bictegravir tablet for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).